Farnesyltransferase inhibitors: Overview of their action and role in solid malignancy therapy

Stefano Margaritora, Alfredo Cesario, Venanzio Porziella, Pierluigi Granone, Alessia Catassi, Patrizia Russo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Nowadays, molecular targeted cancer therapies represent the core of translational research. Protein prenylation [covalent binding of either a farnesyl (15-C) or a geranylgeranyl (20-C) group to the cysteine residue located in the Tetrapeptide CAAX] is required for the localization and function of different proteins critical to signal transduction pathways and cytoskeleton organization. In this group of molecules we find the Ras proteins. Due to the functional role of Ras farnesylation, farnesyltransferase (FTase) inhibition was thought to be a strategy for interfering with Ras-dependent transformation. When farnesylation is blocked, the function of Ras protein is severely impaired because of the inability of the nonfarnesylated protein to anchor to the membrane. The biology of FTase inhibitors (FTIs) is fascinating since, after substantial investigation and their use in several clinical trials, their exact mechanism of action still remains unclear. In addiction to the RAS ones, FTIs can block the farnesylation of several additional proteins. There are approximately 250 human proteins with literal carboxyl-terminal CAAX motifs (according to Swiss-prot data base). However, most of these contain amino acids at the -AAX positions that make them poor substrates for FTase. At present, several CAAX-containing farnesylated human proteins are currently under investigation as FTIs targets including RhoB, the centromere binding proteins CENP-E and CENP-F, the phosphatase PRL1, 2 and 3, the chaperone protein DnaJ, and Rheb. While the FTIs clearly do not or only partly target Ras, these agents appear to have clinical activity in leukemias and in some solid tumors. This article reviews preclinical and clinical data pertinent to the use of FTIs in solid tumors with special regards to lung cancer where the possible role of FTIs is investigated in the light of possible "translational" trials.

Original languageEnglish
Pages (from-to)26-35
Number of pages10
JournalLetters in Drug Design and Discovery
Volume2
Issue number1
DOIs
Publication statusPublished - Feb 2005

Fingerprint

Farnesyltranstransferase
Prenylation
ras Proteins
Neoplasms
Proteins
HSP40 Heat-Shock Proteins
Protein Prenylation
Molecular Targeted Therapy
Therapeutics
Translational Medical Research
Centromere
Cytoskeleton
Phosphoric Monoester Hydrolases
Cysteine
Signal Transduction
Lung Neoplasms
Carrier Proteins
Leukemia
Clinical Trials
Databases

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Farnesyltransferase inhibitors : Overview of their action and role in solid malignancy therapy. / Margaritora, Stefano; Cesario, Alfredo; Porziella, Venanzio; Granone, Pierluigi; Catassi, Alessia; Russo, Patrizia.

In: Letters in Drug Design and Discovery, Vol. 2, No. 1, 02.2005, p. 26-35.

Research output: Contribution to journalArticle

Margaritora, Stefano ; Cesario, Alfredo ; Porziella, Venanzio ; Granone, Pierluigi ; Catassi, Alessia ; Russo, Patrizia. / Farnesyltransferase inhibitors : Overview of their action and role in solid malignancy therapy. In: Letters in Drug Design and Discovery. 2005 ; Vol. 2, No. 1. pp. 26-35.
@article{f5ecaa4c7c6d4bd3bb8c33de6b6965d4,
title = "Farnesyltransferase inhibitors: Overview of their action and role in solid malignancy therapy",
abstract = "Nowadays, molecular targeted cancer therapies represent the core of translational research. Protein prenylation [covalent binding of either a farnesyl (15-C) or a geranylgeranyl (20-C) group to the cysteine residue located in the Tetrapeptide CAAX] is required for the localization and function of different proteins critical to signal transduction pathways and cytoskeleton organization. In this group of molecules we find the Ras proteins. Due to the functional role of Ras farnesylation, farnesyltransferase (FTase) inhibition was thought to be a strategy for interfering with Ras-dependent transformation. When farnesylation is blocked, the function of Ras protein is severely impaired because of the inability of the nonfarnesylated protein to anchor to the membrane. The biology of FTase inhibitors (FTIs) is fascinating since, after substantial investigation and their use in several clinical trials, their exact mechanism of action still remains unclear. In addiction to the RAS ones, FTIs can block the farnesylation of several additional proteins. There are approximately 250 human proteins with literal carboxyl-terminal CAAX motifs (according to Swiss-prot data base). However, most of these contain amino acids at the -AAX positions that make them poor substrates for FTase. At present, several CAAX-containing farnesylated human proteins are currently under investigation as FTIs targets including RhoB, the centromere binding proteins CENP-E and CENP-F, the phosphatase PRL1, 2 and 3, the chaperone protein DnaJ, and Rheb. While the FTIs clearly do not or only partly target Ras, these agents appear to have clinical activity in leukemias and in some solid tumors. This article reviews preclinical and clinical data pertinent to the use of FTIs in solid tumors with special regards to lung cancer where the possible role of FTIs is investigated in the light of possible {"}translational{"} trials.",
author = "Stefano Margaritora and Alfredo Cesario and Venanzio Porziella and Pierluigi Granone and Alessia Catassi and Patrizia Russo",
year = "2005",
month = "2",
doi = "10.2174/1570180053398361",
language = "English",
volume = "2",
pages = "26--35",
journal = "Letters in Drug Design and Discovery",
issn = "1570-1808",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Farnesyltransferase inhibitors

T2 - Overview of their action and role in solid malignancy therapy

AU - Margaritora, Stefano

AU - Cesario, Alfredo

AU - Porziella, Venanzio

AU - Granone, Pierluigi

AU - Catassi, Alessia

AU - Russo, Patrizia

PY - 2005/2

Y1 - 2005/2

N2 - Nowadays, molecular targeted cancer therapies represent the core of translational research. Protein prenylation [covalent binding of either a farnesyl (15-C) or a geranylgeranyl (20-C) group to the cysteine residue located in the Tetrapeptide CAAX] is required for the localization and function of different proteins critical to signal transduction pathways and cytoskeleton organization. In this group of molecules we find the Ras proteins. Due to the functional role of Ras farnesylation, farnesyltransferase (FTase) inhibition was thought to be a strategy for interfering with Ras-dependent transformation. When farnesylation is blocked, the function of Ras protein is severely impaired because of the inability of the nonfarnesylated protein to anchor to the membrane. The biology of FTase inhibitors (FTIs) is fascinating since, after substantial investigation and their use in several clinical trials, their exact mechanism of action still remains unclear. In addiction to the RAS ones, FTIs can block the farnesylation of several additional proteins. There are approximately 250 human proteins with literal carboxyl-terminal CAAX motifs (according to Swiss-prot data base). However, most of these contain amino acids at the -AAX positions that make them poor substrates for FTase. At present, several CAAX-containing farnesylated human proteins are currently under investigation as FTIs targets including RhoB, the centromere binding proteins CENP-E and CENP-F, the phosphatase PRL1, 2 and 3, the chaperone protein DnaJ, and Rheb. While the FTIs clearly do not or only partly target Ras, these agents appear to have clinical activity in leukemias and in some solid tumors. This article reviews preclinical and clinical data pertinent to the use of FTIs in solid tumors with special regards to lung cancer where the possible role of FTIs is investigated in the light of possible "translational" trials.

AB - Nowadays, molecular targeted cancer therapies represent the core of translational research. Protein prenylation [covalent binding of either a farnesyl (15-C) or a geranylgeranyl (20-C) group to the cysteine residue located in the Tetrapeptide CAAX] is required for the localization and function of different proteins critical to signal transduction pathways and cytoskeleton organization. In this group of molecules we find the Ras proteins. Due to the functional role of Ras farnesylation, farnesyltransferase (FTase) inhibition was thought to be a strategy for interfering with Ras-dependent transformation. When farnesylation is blocked, the function of Ras protein is severely impaired because of the inability of the nonfarnesylated protein to anchor to the membrane. The biology of FTase inhibitors (FTIs) is fascinating since, after substantial investigation and their use in several clinical trials, their exact mechanism of action still remains unclear. In addiction to the RAS ones, FTIs can block the farnesylation of several additional proteins. There are approximately 250 human proteins with literal carboxyl-terminal CAAX motifs (according to Swiss-prot data base). However, most of these contain amino acids at the -AAX positions that make them poor substrates for FTase. At present, several CAAX-containing farnesylated human proteins are currently under investigation as FTIs targets including RhoB, the centromere binding proteins CENP-E and CENP-F, the phosphatase PRL1, 2 and 3, the chaperone protein DnaJ, and Rheb. While the FTIs clearly do not or only partly target Ras, these agents appear to have clinical activity in leukemias and in some solid tumors. This article reviews preclinical and clinical data pertinent to the use of FTIs in solid tumors with special regards to lung cancer where the possible role of FTIs is investigated in the light of possible "translational" trials.

UR - http://www.scopus.com/inward/record.url?scp=14344251019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14344251019&partnerID=8YFLogxK

U2 - 10.2174/1570180053398361

DO - 10.2174/1570180053398361

M3 - Article

AN - SCOPUS:14344251019

VL - 2

SP - 26

EP - 35

JO - Letters in Drug Design and Discovery

JF - Letters in Drug Design and Discovery

SN - 1570-1808

IS - 1

ER -